Methods for the use of inhibitors of cytosolic phospholipase A2

US7605156B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• John C. McKew · Ames, US
• Steve Y. Tam · Wellesley, US
• Katherine Lin Lee · Newton, US
• Lihren Chen · Cambridge, US
• Paresh Thakker · Boston, US
• Fuk-Wah Sum · Pomona, US
• Mark Behnke · Somerville, US
• Baihua Hu · Audubon, US
• James D. Clark · Acton, US
• Wei Li · Acton, US
• Valerie Clerin · Watertown, US
• Suzana Marusic · Reading, US
• Kevin Pong · Lawrence, US

Key dates

• Filing date: May 27, 2005
• Grant date: Oct 20, 2009
• Expiry date: Aug 20, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides methods for the use of substituted indole compounds of the general formula:and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.